Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), has invetsted in AMF-regulated investment company AdBio partners’ second fund – AFB Fund II.
Inserm Transfert joins the international limited partners who have invested in AdBio partners’ second fund. The initial closing announced in September 2021 reached €86 million ($102M). Among these other investors are the European Investment Fund (EIF), the French Seed Fund 2 (FNA 2), managed by Bpifrance on behalf of the French State as part of the future investments program, Boehringer Ingelheim Venture Fund, Pierre Fabre, various family offices and the management of AdBio partners.
Inserm Transfert has helped startups from Inserm raise over €1.66 billion ($1.78bn) since 2010. Around a dozen startups are created every year based on innovations researched by Inserm.
